Home ›
Entities
› academia
› <scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
<scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Research article (British Journal of Dermatology, 2019) · cited 64× · AI/ML
AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Summary
AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis is a scholarly article[1].
Key Facts
AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). <scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Retrieved May 24, 2026, from https://4ort.xyz/entity/scp-auriel-scp-pso-a-randomized-doubleblind-phase-scp-iii-scp-equivalence-trial-to-demonstrate-the-clinical-similarity-o
MLA“<scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/scp-auriel-scp-pso-a-randomized-doubleblind-phase-scp-iii-scp-equivalence-trial-to-demonstrate-the-clinical-similarity-o.
BibTeX@misc{4ortxyz_scp-auriel-scp-pso-a-randomized-doubleblind-phase-scp-iii-scp-equivalence-trial-to-demonstrate-the-clinical-similarity-o_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{<scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis}}, year = {2026}, url = {https://4ort.xyz/entity/scp-auriel-scp-pso-a-randomized-doubleblind-phase-scp-iii-scp-equivalence-trial-to-demonstrate-the-clinical-similarity-o}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): <scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis — https://4ort.xyz/entity/scp-auriel-scp-pso-a-randomized-doubleblind-phase-scp-iii-scp-equivalence-trial-to-demonstrate-the-clinical-similarity-o (retrieved 2026-05-24)
